Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’

Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” as a potential best-in-class next-generation GABA-AT inhibitor, telling investors that OV329 has shown over 100x potency over first-generation GABA-AT inhibitor vigabatrin and has been designed to avoid ocular toxicity.